• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Secondary Validation of the Parosmia Olfactory Dysfunction Outcomes Rating (DisODOR): Analysis of a Randomized Clinical Trial.

作者信息

Peterson Andrew M, Kallogjeri Dorina, Islam Aseeyah A, Piccirillo Jay F, Crock Lara W, Farrell Nyssa Fox

机构信息

Department of Otolaryngology - Head and Neck Surgery, Washington University School of Medicine in St. Louis, MO, USA.

Department of Anesthesiology, Division of Pain Management, Washington University School of Medicine in St. Louis, MO, USA.

出版信息

Ann Otol Rhinol Laryngol. 2025 Jul 29:34894251359826. doi: 10.1177/00034894251359826.

DOI:10.1177/00034894251359826
PMID:40728047
Abstract

BACKGROUND

The DisODOR is the only validated disease-specific patient-reported outcome measure (PROM) for patients with parosmia. No published data supports the use of the instrument to monitor response after an intervention. The objective of this study was to secondarily analyze a randomized clinical trial (RCT) to assess the instrument's responsiveness to change.

METHODS

A double-blinded, placebo-controlled RCT with parosmic patients undergoing stellate ganglion block was conducted. The DisODOR was completed at baseline and 3 months, and the Clinical Global Impression - Improvement (CGI-I) score, which is a 7-point Likert scale assessing response of smell distortion to treatment, was given at 3 months. The primary outcome measure of this study was the responsiveness to change of the DisODOR. The secondary outcome measures were the instrument's internal consistency measured via Cronbach's alpha and test-retest reliability calculated by Pearson correlation.

RESULTS

A total of 46 participants with a mean (SD) age of 44 (12) years were analyzed. At 3-month follow-up, there was a mean (SD) change in DisODOR score of -47 (15) for participants reporting much improved (n = 5), -35 (17) for moderately improved (n = 9), -29 (20) for slightly improved (n = 3), and -4 (13) for no change (n = 25) (eta squared [η] = .63). Four patients reported worsening of parosmia with a mean (SD) change in DisODOR score of 11 (16). The internal consistency was excellent at .91 and test-retest reliability strong at .85 (95% CI = 0.68-0.93).

CONCLUSION

This study provided RCT-level evidence for the DisODOR's strong responsiveness to change, internal consistency, and test-retest reliability. The instrument is an ideal PROM for both clinical use and research, particularly given the difficulty in otherwise quantifying parosmia severity.

摘要

相似文献

1
Secondary Validation of the Parosmia Olfactory Dysfunction Outcomes Rating (DisODOR): Analysis of a Randomized Clinical Trial.
Ann Otol Rhinol Laryngol. 2025 Jul 29:34894251359826. doi: 10.1177/00034894251359826.
2
Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction.预防持续性 COVID-19 后嗅觉功能障碍的干预措施。
Cochrane Database Syst Rev. 2022 Sep 5;9(9):CD013877. doi: 10.1002/14651858.CD013877.pub3.
3
Pharmacotherapy for anxiety and comorbid alcohol use disorders.焦虑症合并酒精使用障碍的药物治疗
Cochrane Database Syst Rev. 2015 Jan 20;1(1):CD007505. doi: 10.1002/14651858.CD007505.pub2.
4
Systemic and topical antibiotics for chronic rhinosinusitis.用于慢性鼻-鼻窦炎的全身及局部用抗生素
Cochrane Database Syst Rev. 2016 Apr 26;4(4):CD011994. doi: 10.1002/14651858.CD011994.pub2.
5
Short-course oral steroids alone for chronic rhinosinusitis.短期口服类固醇单独用于慢性鼻窦炎。
Cochrane Database Syst Rev. 2016 Apr 26;4(4):CD011991. doi: 10.1002/14651858.CD011991.pub2.
6
Urodynamics tests for the diagnosis and management of male bladder outlet obstruction: long-term follow-up of the UPSTREAM non-inferiority RCT.用于男性膀胱出口梗阻诊断和管理的尿动力学检查:UPSTREAM非劣效性随机对照试验的长期随访
Health Technol Assess. 2025 Jul;29(26):1-57. doi: 10.3310/SLPT4675.
7
Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.运动神经元病/肌萎缩侧索硬化症患者流涎(唾液过多)的治疗。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD006981. doi: 10.1002/14651858.CD006981.pub3.
8
Antidepressants for depression in adults with HIV infection.用于感染HIV的成年抑郁症患者的抗抑郁药。
Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD008525. doi: 10.1002/14651858.CD008525.pub3.
9
Bioengineered nerve conduits and wraps for peripheral nerve repair of the upper limb.生物工程神经导管和套用于上肢周围神经修复。
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD012574. doi: 10.1002/14651858.CD012574.pub2.
10
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.